The Cross-Border Biotech Blog

Part4_Biotech_Black_Box

Information – some of the free sources    In most cases, you will be assessing a company, a product or a technology. The valuation of the stream of expenses and revenues for the development and commercialization of a product or a service is the simplest situation. If you are valuing a company, you are valuing […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for February 23rd, 2015!   This week’s post covers the last two weeks of activity due to last week’s family day holiday for parts of Canada. The last two weeks saw a lot of activity on the financing front, with Transition Therapeutics raising about $20 million in a public […]

read more


CSRFeatImg

Welcome to your Canada in Science Review for February 20th, 2015! Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1898-903. Chemodetection in fluctuating environments: Receptor coupling, buffering, and antagonism.   N Engl J Med. 2015 Feb 5;372(6):519-27. Efficacy of a device to narrow the coronary sinus in refractory angina.   Proc Natl Acad Sci U S […]

read more


Part_3_BiotechBlackBox

More complicated – and useful – mathematics   In Part 2 of this blog series, we looked at some basic investment mathematics – the time value of money, NPV and the risk-free cost of capital. However, nothing in biotech is risk-free and the risks associated with biotech can be large and numerous. In this blog, […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for February 9th, 2015!   This week saw Actavis and AstraZeneca announce that AstraZeneca will acquire the rights to Actavis’ branded respiratory business in the U.S. and Canada for an initial consideration of about $600 million, with royalties tied to revenues. Further, Valeant Pharmaceuticals announced that they’ve entered into […]

read more


Logo_RB

  Many in our industry remember the golden era during the mid-1990’s when biotech flourished in Canada. At that time, there was a thriving group of biotech companies supported by a varied cast of players that helped these companies push their projects forward. This included the Canadian regional arms of all the large pharma’s, which contributed […]

read more


CSRFeatImg

Welcome to your Canada in Science Review for February 6th, 2015! Science. 2015 Jan 9;347(6218):1254806. doi: 10.1126/science.1254806. RNA splicing. The human splicing code reveals new insights into the genetic determinants of disease.   Nature. 2014 Dec 11;516(7530):198-206. doi: 10.1038/nature14046. Genome-wide characterization of the routes to pluripotency.   Lancet. 2014 Oct 25;384(9953):1513-20. doi: 10.1016/S0140-6736(14)60153-7. Oral 9-cis retinoid for childhood […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for February 2nd, 2015!   This week, Endo International plc announced that it completed the acquisition of Auxilium Pharmaceuticals Inc., in a transaction valued at $2.6 billion when it was announced on October 9, 2014.  Endo’s portfolio now has a broader offering of urology and orthopedic products, including XIAFLEX®, TESTOPEL® […]

read more


Part_2_BiotechBlackBox

Some basic mathematics   When you create a valuation spreadsheet, you are plugging in estimates of revenues and expenses which are going to occur over several years, if not a couple decades. When you do the basic addition and subtraction in this spreadsheet, you hopefully end up with a positive number because, if the number […]

read more